Literature DB >> 26834932

Cost of Treatment for Relapsed/Refractory Multiple Myeloma.

Safiya Abouzaid, Craig Gibson, Yasir Nagarwala1.   

Abstract

Entities:  

Year:  2015        PMID： 26834932      PMCID： PMC4719135     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  6 in total

1.  Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.

Authors:  Jesús F San-Miguel; Meletios A Dimopoulos; Edward A Stadtmauer; S Vincent Rajkumar; David Siegel; Marie-Laure Bravo; Marta Olesnyckyj; Robert D Knight; Jerome B Zeldis; Jean-Luc Harousseau; Donna M Weber
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-02

2.  Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.

Authors:  Steven R Arikian; Dejan Milentijevic; Gary Binder; Craig J Gibson; X Henry Hu; Yasir Nagarwala; Mohamad Hussein; Frank A Corvino; Andy Surinach; Saad Z Usmani
Journal:  Curr Med Res Opin       Date:  2015-04-17       Impact factor: 2.580

3.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Authors:  Jesus San Miguel; Katja Weisel; Philippe Moreau; Martha Lacy; Kevin Song; Michel Delforge; Lionel Karlin; Hartmut Goldschmidt; Anne Banos; Albert Oriol; Adrian Alegre; Christine Chen; Michele Cavo; Laurent Garderet; Valentina Ivanova; Joaquin Martinez-Lopez; Andrew Belch; Antonio Palumbo; Stephen Schey; Pieter Sonneveld; Xin Yu; Lars Sternas; Christian Jacques; Mohamed Zaki; Meletios Dimopoulos
Journal:  Lancet Oncol       Date:  2013-09-03       Impact factor: 41.316

4.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Authors:  S K Kumar; J H Lee; J J Lahuerta; G Morgan; P G Richardson; J Crowley; J Haessler; J Feather; A Hoering; P Moreau; X LeLeu; C Hulin; S K Klein; P Sonneveld; D Siegel; J Bladé; H Goldschmidt; S Jagannath; J S Miguel; R Orlowski; A Palumbo; O Sezer; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2011-07-29       Impact factor: 11.528

5.  Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

Authors:  Anuja Roy; Jonathan K Kish; Lisa Bloudek; David S Siegel; Sundar Jagannath; Denise Globe; Emil T Kuriakose; Kristen Migliaccio-Walle
Journal:  Am Health Drug Benefits       Date:  2015-06

6.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Authors:  Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson
Journal:  Lancet Oncol       Date:  2014-09-18       Impact factor: 41.316
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.